In lupus haemolytic anaemia, B-cell therapy matched conventional treatment and allowed faster steroid tapering

Design

Multi-campus retrospective comparative cohort

Population

70 patients with first-episode SLE-associated warm AIHA, Hb <90 g/L

Primary outcome

6-month overall response rate

Effect

89.7% vs 85.7%; OR 1.45 (0.19 to 9.61); prednisone 40 vs 50 mg/day at 1 month

This Chinese multi-campus retrospective cohort, published 24 September in Rheumatology, compared B-cell-targeted therapy (rituximab, belimumab or telitacicept) with conventional glucocorticoid-based immunosuppression in 70 patients with a first episode of lupus-associated warm autoimmune haemolytic anaemia and haemoglobin below 90 g/L.

Six-month overall response was 89.7% with B-cell therapy and 85.7% with conventional treatment (OR 1.45, 95% CI 0.19 to 9.61). Complete response was numerically higher (61.5% vs 42.9%), and at 12 months response was 89.3% vs 73.7%, though relapse-free survival did not differ. Prednisone-equivalent dose at one month was lower with B-cell therapy (40 vs 50 mg/day). There were 13 inpatient adverse-event episodes in six months, including deaths.

The B-cell group was younger and had more active lupus, and the study is small. It supports B-cell therapy as a steroid-sparing option in this complication, not as proven superior.

• B-cell-targeted therapy gave response rates similar to conventional treatment in lupus haemolytic anaemia.
• It allowed lower glucocorticoid doses at one month.
• Complete response and 12-month response were numerically, not significantly, higher.
• Serious adverse events occurred in both groups; monitor closely in the first six months.

Why it matters

Offers a route to less steroid exposure in a complication that usually demands high doses.

Don't overread it

Small, retrospective and non-randomised; the telitacicept result comes from seven patients.

The statistics, in plain English

The odds ratio's confidence interval of 0.19 to 9.61 is extremely wide, meaning the study cannot tell whether B-cell therapy is better, worse or the same.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.